Search

Your search keyword '"Wang, Yongfu"' showing total 29 results
Start Over Author "Wang, Yongfu" Publisher elsevier ltd
29 results on '"Wang, Yongfu"'

21. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial

Author

Xu, Huji, Li, Zhijun, Wu, Jian, Xing, Qian, Shi, Guixiu, Li, Juan, Liu, Xu, Wu, Lijun, Li, Xiaomei, Tan, Wenfeng, He, Dongyi, Bi, Liqi, Li, Hongbin, Xiao, Zhengyu, Shuai, Zongwen, Li, Xiaoxia, Wang, Yongfu, Luo, Li, Zheng, Yi, Xiao, Weiguo, Wu, Xin, Zhou, Ling, Li, Ting, Qian, Lei, Zhou, Hui, Lu, Shujie, Zheng, Shirui, Xiong, Yan, Wang, Xiong, Wang, Yanqi, and Wu, Xinjiang

Published
2019
Full Text
View/download PDF

25. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study

Author

Kong, Wen, Chen, Cheng, Wang, Yuejin, Gong, Fengqiu, Guo, Lili, Huang, Zhonghui, Shao, Wenjuan, Sun, Ping, Xue, Chunhua, Zhu, Yiqing, Jiang, Weiping, Gui, Yaxiang, Wang, Hao, Yang, Ping, Yao, Ruiyong, Yin, Wenhua, Chao, Nong, Jiang, Tao, Qian, Baima village:Qinxiao, Shi, Hongqin, Tao, Yungen, Wu, Meiqin, Yang, Yuping, Zhang, Dongmei, Zhang, Guoxian, Wang, Jianguo, Chen, Xiaojun, Ding, Zhaosheng, Fu, Huajie, Hang, Li, Huang, Yu, Jiang, Huiping, Jiang, Huaxin, Li, Junlian, Liu, Baoxia, Pan, Lijun, Shao, Caiyun, Tan, Huixia, Tan, Qiuwei, Wang, Weizhong, Yang, Jianping, Yi, Meiqin, Yin, Qianlu, Yuan, Hua, Zhang, Weixing, Zhu, Hong, Fei, Haojun, Jiang, Liwei, Li, Wenhong, Shen, Zhaoer, Sun, Xiaomei, Tang, Wenjuan, Wang, Mingming, Wu, Jinlong, Zhang, Songqing, Zhang, Xiaozhong, Guan, Ling, Guan, Xueling, Liu, Wantong, Cui, Wei, Lei, Zhaokuan, Wang, Yongming, Yu, Yongmin, Song, Liucun, Wang, Tao, Li, Xiaolong, Luo, Jianrong, Wang, Hebin, Liu, Weiguo, Zhang, Fude, Zhang, Fang, Wang, Yongfu, Zhao, Qingna, Liu, Yinbiao, Li, Jianli, Dan, Liujie, Wang, Dakuan, Yan, Jiaoxia, Zhu, Guofu, Liu, Zisen, He, Zhoulun, Yan, Yongfen, Li, Ping, Shang, Huailiang, Heng, Baichao, Liu, Shuli, Ran, Zhe, Jiang, Kun, Zhu, Xin, Wu, Haibin, Liang, Liling, Yuan, Jianhui, Wang, Zhigang, Meng, Aijing, Wang, Jing, Guan, Xia, Yang, Jiannan, Li, Yan, Liu, Haixia, Wang, Wuying, Liu, Xinhao, Qiao, Fuke, Li, Xianmin, Zhao, Herong, Zhu, Chunyuan, Lu, Yanan, Liu, Ning, Peng, Yanan, Wan, Li, Chen, Hairui, Song, Xiaoming, Lou, Qingtao, Wang, Wei, Liu, Changshui, Zhang, Lijuan, Zhang, Zhanjiang, Yuan, Shijie, Yang, Yongxin, Chen, Suqin, Dong, Changjie, Ran, Jianguo, Wu, Weiling, Li, Zhen, Zhang, Hui, Duan, Liujia, Yang, Fan, Liu, Ying, Wang, Kun, Yan, Lina, Ma, Jiangli, Wan, Liuyan, Li, Yanfen, Wang, Han, Yuan, Bing, Du, Ruiling, Zhang, Jie, Zhang, Jingge, Li, Lin, Zhao, Aihua, Wei, Junhong, Zhao, Ning, Zhu, Yonghui, Mao, Wuyi, Luo, Qi, Huang, Zhongpu, Guo, Hongbin, Zheng, Na, Pan, Weiwei, Qin, Meng, Li, Ying, Xiao, Shanshan, Zhang, Yun, Wu, Weiying, Li, Jing, Song, Liusen, Tang, Yi, Yao, Qineng, Yang, Kunyun, Kuang, Meixiong, Bao, Changlin, Xiao, Tao, Wan, Yanping, Wan, Xiaojie, Liu, Binbin, Jiang, Tieliu, Zhang, Xiaoping, Tan, Zhen, Zhang, Xiaobing, Liu, Zhaoguo, Chen, Zhenhua, Wang, Yu, Yu, Yanyan, Dai, Saibo, Hu, PeiLei, Zhang, Chuanfang, Li, Yanhong, Gong, Dehua, Liu, Liqin, Li, Xiaohong, Ling, Jie, Shan, Xinhua, Zhang, Z huo, Deng, Haibing, Zeng, Zhengbiao, Li, Honghua, Zhou, Shuiping, Xu, Ying, Zhang, Can, Chen, Haifeng, Wang, Xiaoling, Chen, Yao, Yang, Sheng, Peng, Weiping, Sun, Huan, Liao, Hui, Xie, Xiping, Liang, Fang, Hu, Cheng, Hu, Siwei, Liu, Xinyu, Peng, Jun, Liu, Wenxin, Liu, Decheng, Liu, Wenbin, Li, Xiangmei, Guo, Hui, Wang, Wen, He, Yujue, Wang, Bo, Zhang, Yaping, Gao, Qiaofen, Zhao, Jianxi, Chen, Weitao, Li, Qing, Mu, Taojun, Liang, Qijun, Gu, Jixiu, Ma, Ling, An, Ning, Li, Junwen, Yao, Qinhua, Liang, Chengzhi, Ge, Xiuqun, Chen, Yalin, Luan, Shumao, Sun, Yanhong, Yang, Ruifang, Ma, Bin, Zhang, Suiqiang, Liang, Fusheng, Tian, Yuan, Zhang, Hongxia, Yang, Fanqin, Lu, Qifeng, Chen, Jun, Dong, Yan, Zhang, Shunsheng, Jin, Ziming, Wang, Jintao, Lan, Jianwei, Zhang, Zhanjun, Wu, Yumin, Shi, Jianlin, Shi, Zhaoping, Chen, Yan, Ding, Jianxin, An, Xiaofeng, Yang, Jun, Ling, Dongdong, Nie, Zhenzhou, Liu, Chunli, Mi, Guangyin, Ma, Jun, Guo, Jiyun, Gao, Lei, Li, Xiangwei, Liu, Jianmin, Wang, Xinhua, Lu, Wei, Bai, Liqiong, Xin, Henan, Zhang, Haoran, Li, Hengjing, Zhang, Zongde, Ma, Yu, Li, Mufei, Feng, Boxuan, Du, Jiang, Sui, Hongtao, Zhao, Rong, Su, Haoxiang, Pan, Shouguo, Shen, Fei, He, Jian, Yang, Shumin, Si, Hongyan, Cheng, Xu, Xu, Zuhui, Tan, Yunhong, Chen, Tianzhu, Xu, Weiguo, Peng, Hong, Wang, Zhijian, Zhu, Tao, Chen, Xiaoyou, Zhou, Xinhua, and Jin, Qi

Published
2017
Full Text
View/download PDF

29. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study.

Author

Yang Y, Li J, Liu J, Liu L, Wang Y, Hu J, Li Z, Gu J, Zhang X, Xiao Z, Zheng J, Liu L, Li Z, and Wei JC

Abstract

Background: The efficacy and safety of the oral Janus kinase inhibitor peficitinib were investigated in Asian patients with rheumatoid arthritis (RA)., Methods: In this double-blind, phase 3 study, patients from mainland China, Korea, and Taiwan with RA and an inadequate response/intolerance to methotrexate were randomized (1:1:1) to once-daily placebo (N = 128), peficitinib 100 mg (N = 129), or 150 mg (N = 128) in combination with non-biologic DMARDs. At Week 24, patients receiving placebo switched to peficitinib 100 mg or 150 mg. American College of Rheumatology (ACR) 20 response at Week 24/early termination (ET) was the primary endpoint. Adverse events (AEs) were assessed. The study was registered at ClinicalTrials (NCT03660059)., Findings: 385 patients were included in the analysis. ACR20 responses were statistically significantly higher in both peficitinib 100 mg (56.6%) and 150 mg (56.3%) groups versus placebo (24.2%); Odds Ratio (95% confidence interval, CI) 4.14 (2.42, 7.08) and 4.07 (2.38, 6.96), respectively (both P < 0.001) at Week 24/ET. The incidence rate of herpes zoster related disease (herpes zoster and varicella) was higher in patients who received peficitinib versus placebo, but no dose dependency was observed (incidence rate/100 patient-years (95% CI): peficitinib 6.7 (4.32, 10.37); placebo 3.7 (0.93, 14.88)., Interpretation: In Asian patients with RA and an inadequate response/intolerance to methotrexate, peficitinib 100 mg and 150 mg demonstrated superiority to placebo in the reduction of RA symptoms and was well tolerated. No additional benefit was observed with use of the higher peficitinib dose in this study population of predominantly Chinese patients., Funding: Astellas Pharma., Competing Interests: James Cheng-Chung Wei received research grants, speaker fees and/or participated in advisory boards for Abbott, Abbvie, Bristol-Myers Squibb, Celgene, Chugai, Eli Lilly, GSK, JNJ, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB. Yue Yang, Ju Liu, Yongfu Wang, Jingyang Li, Jiankang Hu, Zhijun Li, Jieruo Gu, Lin Liu (Xuzhou Central Hospital), Xiao Zhang, Zhengyu Xiao, and Zhanguo Li report no conflicts of interest. Junjie Zheng and Lin Liu (Astellas) are employees of Astellas Pharma China Inc., (© 2023 Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results